GLP Watchdog

Hers vs Ivy Rx

Hers has an open FDA warning letter dated September 9, 2025. Ivy Rx has none. On compounded semaglutide injection, Ivy Rx costs $24 less a year at standing rates: $197 a month against $199 a month at Hers.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Hers / Ivy Rx

Hers logo

Hers

6.8/10

Ivy Rx logo

Ivy Rx

7.3/10

FDA warning letters
None on record
Pharmacy
None named in our record
Lowest standing price
$199/moCompounded semaglutide injection
$197/moCompounded semaglutide injection
States
All 50 states
All 50 states
Checked
Prices captured Record checked September 2026
Prices captured Record checked October 2026
Visit Hers
Visit Ivy Rx

Neither Hers nor Ivy Rx pays us. Links to them earn nothing. Scores: Hers 6.8, Ivy Rx 7.3. How we are paid

What the record shows

  1. 01

    Hers has an open FDA warning letter dated September 9, 2025. Ivy Rx has none.

  2. 02

    Hers names three pharmacies. Ivy Rx names no compounding pharmacy in our record.

  3. 03

    On compounded semaglutide injection, Ivy Rx costs $24 less a year at standing rates: $197 a month against $199 a month at Hers.

  4. 04

    Only Hers lists a price for brand-name tirzepatide pen. Only Ivy Rx lists a price for compounded tirzepatide injection.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Hers

Ivy Rx

Compounded semaglutide injection

$199/mo

$2,388 a year

$197/moLower

$2,364 a year

Compounded tirzepatide injection
Not sold or not priced

$297/mo

$3,564 a year

Brand-name tirzepatide pen

$299/mo

medication only, membership extra; not compared

Not sold or not priced
Price includes
Medication
Medication, clinician visits, shipping
Billed separately
Clinician visits, coaching
Not stated
Cancel any time
Yes, stated
Yes, stated
Minimum term
None
None
Refunds
No refund guaranteed once the pharmacy has processed an order
All transactions are final; no returns
Early-exit fee
Not stated
None stated

Read off each seller’s own pages. Hers: September 28, 2026. Ivy Rx: July 10, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Hers

6.8/10
  • Sells brand-name tirzepatide pen, which Ivy Rx does not price
  • Names its compounding pharmacy
  • Open FDA warning letter, September 9, 2025
  • Price leaves out clinician visits and coaching
Visit Hers

The case for Ivy Rx

7.3/10
  • No FDA warning letter on record
  • $24 a year less on compounded semaglutide injection
  • Sells compounded tirzepatide injection, which Hers does not price
  • Price includes clinician visits
  • Names no compounding pharmacy
Visit Ivy Rx

Scores

Hers 6.8 · Ivy Rx 7.3 out of 10. Six weighted parts.

Value25%

3.0A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

7.0A
vs
B
7.5

Accessibility10%

10.0A
vs
B
10.0

Support10%

3.0A
vs
B
7.0

The score is the same formula for every seller. Payment does not enter it. Method

Hers vs Ivy Rx: questions

Hers has an open FDA warning letter dated September 9, 2025. Ivy Rx has none. Letters are matched to a seller by company, domain and address, never by a similar name.
Hers names three pharmacies. Ivy Rx names no compounding pharmacy in our record.
Ivy Rx, by $24 a year at standing rates. Hers: $199 a month, about $2,388 a year. Ivy Rx: $197 a month, about $2,364 a year.
Hers states you can cancel at any time; refunds: no refund guaranteed once the pharmacy has processed an order. Ivy Rx states you can cancel at any time; refunds: all transactions are final; no returns.
Neither Hers nor Ivy Rx pays us. Links to them earn nothing. Scores: Hers 6.8, Ivy Rx 7.3.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks